Latest News
The Katz Laboratory in the Department of Pathology at Yale School of Medicine seeks applicants for an open Postdoctoral position.
- April 12, 2022
Faculty and staff of Yale Pathology went to the Water’s Edge Resort in Madison on April 2 for a full-day retreat, the department’s first in-person gathering since the coronavirus pandemic began more than two years ago.
- March 18, 2022
Pathologists and research scientists from Department of Pathology at Yale School of Medicine will be involved in more than 40 presentations and sessions at the United States and Canadian Academy of Pathology (USCAP) 2022 Annual Meeting in Los Angeles March 19-24.
- January 31, 2022
A new Yale study reveals that astrocytes, a type of glial cell found in the central nervous system, develop at different rates in male and female mice, differences that could affect how neural networks are constructed and may have implications for disease risk. The findings were published Feb. 1 in Cell Reports.
- September 01, 2021Source: GEN
Scientists based at Yale University have been using multiplexed error robust fluorescence in situ hybridization (MERFISH) to investigate the spatial transcriptome profiles of individual cells in intact tissue.
- October 01, 2020
Congratulations to Samuel Kerr for Receiving the NIH F31 NRSA Fellowship!
- December 09, 2017Source: New Haven Register
The battle against cancer is increasingly being fought on the genetic level, and Dr. Samuel Katz is aiding the body’s immune system by creating safer, more effective weapons. His research is focused on treating cancers of the blood, such as multiple myeloma, Hodgkin’s lymphoma and acute myeloid leukemia, but his technique could eventually be used against solid tumors as well, including cancers of the breast, ovary, pancreas and colon. Most gene therapy uses genetically modified DNA in the body’s T lymphocytes — a type of white blood cell that is an integral part of the body’s immune system — to find, attack and kill cancer cells.
- October 23, 2017Source: WTNH News Channel 8
Support from ACGT has Dr. Samuel Katz at Yale School of Medicine refining the current research. He is reprogramming cells, with RNA, the genetic material that delivers the message, to destroy the cancerous ones — acting as soldiers in battle, if you will. “We give them the message,” says Dr. Katz, “and then the message goes away, and when the soldier is done with his job he returns back to normal.” If successful, this approach will make safer and stronger cells – a super-soldier that reintegrates into society when the war is won.
- June 25, 2014Source: Office of Connecticut Governor Dannel P. Malloy
Researchers from Yale, Wesleyan, UConn and The Jackson Laboratory will share a total of nearly $10 million in state grants earmarked for stem cell research.
- June 24, 2014Source: New Haven Register
Yale researchers received a total of $5.6 million for stem cell research out of $10 million given to 18 state-based researchers, according to a release Tuesday from Gov. Dannel P. Malloy.